erlotinib hydrochloride has been researched along with phosphotyrosine in 8 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (phosphotyrosine) | Trials (phosphotyrosine) | Recent Studies (post-2010) (phosphotyrosine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 6,475 | 4 | 751 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arnold, LD; Baker, DA; Barbacci, EG; Davis, JA; Doty, JL; Iwata, KK; Morin, MJ; Moyer, JD; Pollack, VA; Pustilnik, LR; Savage, DM; Sloan, DE; Smolarek, TA; Tsaparikos, KE; Vaidya, MP | 1 |
| Fenyo, D; Gibson, N; Griffin, G; Haley, JD; Hunt, T; Iwata, K; Petti, F; Settinari, T; Thelemann, A | 1 |
| Bartholomeusz, C; Hortobagyi, GN; Kurisu, K; Sudo, T; Ueno, NT; Yamasaki, F; Zhang, D | 1 |
| Boronina, T; Cole, PA; Cole, RN; Kavran, JM; Leahy, DJ; Longo, PA; Qiu, C; Tarrant, MK | 1 |
| Broxterman, HJ; Jiménez, CR; Knol, JC; Labots, M; Pham, TV; Piersma, SR; van der Mijn, JC; Verheul, HM | 1 |
| Abe, Y; Adachi, J; Nagano, M; Tada, A; Tomonaga, T | 1 |
| Awasthi, S; Bansal, M; Belkina, N; Biswas, R; Califano, A; Chaerkady, R; Charles Jacob, HK; Cultraro, CM; Gao, S; Guha, U; Kashyap, MK; Kirkali, G; Maity, T; Marimuthu, A; Pandey, A; Pitts, S; Singh, S; Venugopalan, A; Zhang, X | 1 |
| Chen, X; Chu, B; Feng, S; Ke, M; Kong, Q; Lu, Y; Qin, Y; Tian, R; Zheng, Z | 1 |
8 other study(ies) available for erlotinib hydrochloride and phosphotyrosine
| Article | Year |
|---|---|
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Cisplatin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Phosphorylation; Phosphotyrosine; Polypharmacy; Quinazolines; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine | 1999 |
Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells.
Topics: Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Chromatography, Affinity; Chromatography, Liquid; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoblotting; Isotopes; Mass Spectrometry; Models, Biological; Peptide Mapping; Phosphorylation; Phosphotyrosine; Proteins; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; src-Family Kinases | 2005 |
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Genes, Dominant; Humans; Phosphorylation; Phosphotyrosine; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Transfection | 2007 |
In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.
Topics: Amino Acid Sequence; Cell Line; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kinetics; Lapatinib; Molecular Sequence Data; Mutant Proteins; Phosphopeptides; Phosphorylation; Phosphotyrosine; Quinazolines; Time Factors | 2009 |
Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics.
Topics: Antibodies, Neoplasm; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mass Spectrometry; Phosphoproteins; Phosphotyrosine | 2015 |
Deep Phosphotyrosine Proteomics by Optimization of Phosphotyrosine Enrichment and MS/MS Parameters.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromatography, Liquid; Databases, Protein; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Mitogen-Activated Protein Kinase 13; Neoplasm Proteins; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Proteomics; Signal Transduction; Tandem Mass Spectrometry; Tyrosine | 2017 |
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Isotope Labeling; Lung Neoplasms; Mass Spectrometry; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proteomics; Quinazolines; Reproducibility of Results; Signal Transduction; Tyrosine | 2017 |
High-Throughput Phosphotyrosine Protein Complexes Screening by Photoaffinity-Engineered Protein Scaffold-Based Forward-Phase Protein Array.
Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; GRB2 Adaptor Protein; High-Throughput Screening Assays; Humans; Phosphotyrosine; Protein Array Analysis; Protein Binding; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; src Homology Domains; Ultraviolet Rays | 2019 |